**Core Concept:** Imatinib is a specific tyrosine kinase inhibitor used in the treatment of certain types of cancers. Tyrosine kinase inhibitors are drugs that block the activity of enzymes called tyrosine kinases, which are involved in cell growth and division. Imatinib is particularly effective against mutations involving the BCR-ABL gene, which is commonly found in chronic myeloid leukemia (CML) and some cases of gastrointestinal stromal tumors (GISTs).

**Why the Correct Answer is Right:** Imatinib is specifically designed to target the BCR-ABL tyrosine kinase, which is involved in the uncontrolled growth and division of cells in CML and some GISTs. By inhibiting BCR-ABL, Imatinib halts the progression of these cancers and allows the immune system to clear the remaining cancerous cells.

**Why Each Wrong Option is Incorrect:**

A. Chronic myeloid leukemia (CML) is a type of cancer that affects white blood cells, and Imatinib is an effective treatment for CML, making it incorrect to state that Imatinib is not used to treat this condition.

B. Gastrointestinal stromal tumors (GISTs) are a type of cancer that originates from cells called c-KIT or platelet-derived growth factor receptor (PDGFRA) positive cells. Imatinib is effective against GISTs with specific mutations involving c-KIT or PDGFRA.

C. Although Imatinib is effective against certain types of cancer, stating that it is not used for any cancer is incorrect. Imatinib is used for CML and some GISTs but not for all types of cancer.

D. Imatinib is a tyrosine kinase inhibitor, targeting specific mutations involving BCR-ABL in CML and certain GISTs.

**Clinical Pearl:** Imatinib is a crucial medication for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and gastrointestinal stromal tumors (GISTs) with specific mutations involving c-KIT or PDGFRA. It is essential for clinicians to accurately diagnose the specific genetic mutations to ensure appropriate treatment with Imatinib.